1
|
Brieva-Toloza AV, Hovmand OR, Micali N, Christensen AB. Let's get aligned! Developing a core outcome set for clinical trials in eating disorders. EUROPEAN EATING DISORDERS REVIEW 2024; 32:652-661. [PMID: 38389169 DOI: 10.1002/erv.3079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 01/30/2024] [Accepted: 02/03/2024] [Indexed: 02/24/2024]
Abstract
OBJECTIVE Our study aimed to review the outcome measures/assessment instruments used and to assess their heterogeneity/homogeneity in eating disorders (EDs) randomised controlled trials. METHODS APA PsycInfo, PubMed, and Embase were searched in December 2022 to identify studies published between and inclusive of January 2012 and December 2022. Inclusion/exclusion criteria were: (1) complete articles published in peer-reviewed scientific journals, which were: (2) randomised trials, (3) in a clinical setting (4) with human subjects, (5) with an ICD or DSM diagnosis of Anorexia Nervosa, Binge Eating Disorder, or Bulimia Nervosa. The selected papers also: (6) used one or more standardised instruments designed to measure one or more psychometric characteristics associated with ED as a primary or secondary outcome, as judged by the authors of this systematic review, and (7) were published in English or Danish. RESULTS Ninety one articles were included, and a total of 196 outcome measures were collected. DISCUSSION The diversity of outcome measures in ED trials hampers result comparability and data integration. We suggest creating a core outcome measure set using the Delphi method, including clinician and patient-reported ED assessments, along with relevant comorbidity scales.
Collapse
Affiliation(s)
- Anna Victoria Brieva-Toloza
- Eating Disorders Research Unit, Psychiatric Centre Ballerup, Mental Health Services in the Capital Region of Denmark, Copenhagen, Denmark
| | - Oliver Rumle Hovmand
- Psychiatric Research Unit, Region Zealand Mental Health Service, Slagelse, Denmark
- Department of Clinical Medicine, Faculty of Health, University of Copenhagen, Copenhagen, Denmark
| | - Nadia Micali
- Eating Disorders Research Unit, Psychiatric Centre Ballerup, Mental Health Services in the Capital Region of Denmark, Copenhagen, Denmark
- Great Ormond Street Institute of Child Health, University College London, London, UK
| | - Anne Bryde Christensen
- Eating Disorders Research Unit, Psychiatric Centre Ballerup, Mental Health Services in the Capital Region of Denmark, Copenhagen, Denmark
- Department of Psychology, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
2
|
Kogetsu A, Isono M, Aikyo T, Furuta J, Goto D, Hamakawa N, Hide M, Hori R, Ikeda N, Inoi K, Kawagoe N, Kubota T, Manabe S, Matsumura Y, Matsuyama K, Nakai T, Nakao I, Saito Y, Senoo M, Takahashi MP, Takeda T, Takei M, Tamai K, Tanaka A, Torashima Y, Tsuchida Y, Yamasaki C, Yamamoto BA, Kato K. Enhancing evidence-informed policymaking in medicine and healthcare: stakeholder involvement in the Commons Project for rare diseases in Japan. RESEARCH INVOLVEMENT AND ENGAGEMENT 2023; 9:107. [PMID: 38031179 PMCID: PMC10685685 DOI: 10.1186/s40900-023-00515-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Accepted: 11/14/2023] [Indexed: 12/01/2023]
Abstract
BACKGROUND Although stakeholder involvement in policymaking is attracting attention in the fields of medicine and healthcare, a practical methodology has not yet been established. Rare-disease policy, specifically research priority setting for the allocation of limited research resources, is an area where evidence generation through stakeholder involvement is expected to be effective. We generated evidence for rare-disease policymaking through stakeholder involvement and explored effective collaboration among stakeholders. METHODS We constructed a space called 'Evidence-generating Commons', where patients, family members, researchers, and former policymakers can share their knowledge and experiences and engage in continual deliberations on evidence generation. Ten rare diseases were consequently represented. In the 'Commons', 25 consecutive workshops were held predominantly online, from 2019 to 2021. These workshops focused on (1) clarification of difficulties faced by rare-disease patients, (2) development and selection of criteria for priority setting, and (3) priority setting through the application of the criteria. For the first step, an on-site workshop using sticky notes was held. The data were analysed based on KJ method. For the second and third steps, workshops on specific themes were held to build consensus. The workshop agendas and methods were modified based on participants' feedback. RESULTS The 'Commons' was established with 43 participants, resulting in positive effects such as capacity building, opportunities for interactions, mutual understanding, and empathy among the participants. The difficulties faced by patients with rare diseases were classified into 10 categories. Seven research topics were identified as priority issues to be addressed including 'impediments to daily life', 'financial burden', 'anxiety', and 'burden of hospital visits'. This was performed by synthesising the results of the application of the two criteria that were particularly important to strengthen future research on rare diseases. We also clarified high-priority research topics by using criteria valued more by patients and family members than by researchers and former policymakers, and criteria with specific perspectives. CONCLUSION We generated evidence for policymaking in the field of rare diseases. This study's insights into stakeholder involvement can enhance evidence-informed policymaking. We engaged in comprehensive discussions with policymakers regarding policy implementation and planned analysis of the participants' experiences in this project.
Collapse
Affiliation(s)
- Atsushi Kogetsu
- Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Japan.
| | - Moeko Isono
- Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Japan
| | - Tatsuki Aikyo
- Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Japan
- School of Medicine, Hiroshima University, Hiroshima, Japan
| | - Junichi Furuta
- Department of Medical Informatics and Management, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Dai Goto
- Department of Stem Cell Therapy Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Nao Hamakawa
- Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Japan
| | - Michihiro Hide
- Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Japanese Society of Tuberous Sclerosis Complex Family Net Committee, Yokohama, Kanagawa, Japan
| | - Risa Hori
- Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Noriko Ikeda
- Commons Project, Osaka University, Suita, Osaka, Japan
| | - Keiko Inoi
- NPO Japan Marfan Association, Kuwana, Mie, Japan
| | - Naomi Kawagoe
- MECP2 Duplication Syndrome Family Association, Suita, Osaka, Japan
| | - Tomoya Kubota
- Department of Clinical Laboratory and Biomedical Sciences, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Shirou Manabe
- Department of Transformative System for Medical Information, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Yasushi Matsumura
- Osaka National Hospital, Osaka, Japan
- Department of Medical Informatics, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | | | - Tomoko Nakai
- Japanese Huntington's Disease Network (JHDN), Tokyo, Japan
| | | | - Yuki Saito
- Commons Project, Osaka University, Suita, Osaka, Japan
| | - Midori Senoo
- NPO Myotonic Dystrophy Patients' Group of Japan (DM-Family), Tokyo, Japan
| | - Masanori P Takahashi
- Department of Clinical Laboratory and Biomedical Sciences, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Toshihiro Takeda
- Department of Medical Informatics, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Megumi Takei
- Japanese Society of Tuberous Sclerosis Complex Family Net Committee, Yokohama, Kanagawa, Japan
| | - Katsuto Tamai
- Department of Stem Cell Therapy Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Akio Tanaka
- Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Yasuhiro Torashima
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Yuya Tsuchida
- NPO Myotonic Dystrophy Patients' Group of Japan (DM-Family), Tokyo, Japan
| | - Chisato Yamasaki
- Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Japan
- Center for Intractable Diseases and ImmunoGenomics (CiDIC), Health and Nutrition (NIBIOHN), National Institutes of Biomedical Innovation, Ibaraki, Osaka, Japan
| | - Beverley Anne Yamamoto
- HAEJ, Non-Profit Patient Organization for Hereditary Angioedema in Japan, Kakogawa, Hyogo, Japan
- HAEi, Non-Profit International Patient Organization for Hereditary Angioedema Registered in the US, Fairfax City, VA, USA
- Graduate School of Human Sciences, Osaka University, Suita, Osaka, Japan
| | - Kazuto Kato
- Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Japan.
| |
Collapse
|